Inorganic nanoparticles of high density to destroy cells in-vivo
The present application relates to novel excitable particles which can be used in the health sector. It more particularly relates to particles which can generate electrons and/or high energy photon when excited by ionizing radiations such as X-Rays, γ-Rays, radioactive isotope and/or electron beams, and to the uses thereof in health, in particular in human health. The inventive particles are made of an inorganic material comprising oxygen, in particular an oxide, said material having an adequate density, and can be activated in vitro, ex vivo, or in vivo, by controllable external excitation, in order to disturb, alter or destroy target cells, tissues or organs. The invention also relates to methods for the production of said particles, and to pharmaceutical or medical device compositions containing same.
1. A method for altering, destroying or eliminating target cells in an animal by i) administering a nanoparticle or nanoparticle aggregate or a composition comprising the nanoparticle or nanoparticle aggregate, wherein the nanoparticle or nanoparticle aggregate consists of a metal oxide coated with a biocompatible coating, wherein the density of the nanoparticle or the density of the nanoparticle aggregate is at least 7 g/cm 3 , and the nanoparticle or nanoparticle aggregate is covered with a biocompatible coating providing the nanoparticle or the nanoparticle aggregate stability between pH 6.5 and 7.5 in a physiological fluid, and ii) exposing said animal to ionizing radiations.
2. The method according to claim 1 , wherein the metal oxide is selected from the group consisting of CeO 2 , Nd 2 O 3 , Sm 2 O 3 , Eu 2 O 3 , Gd 2 O 3 , Tb 2 O 3 , Dy 2 O 3 , Ho 2 O 3 , Er 2 O 3 , Tm 2 O 3 , Yb 2 O 3 , Lu 2 O 3 , HfO 2 , TaO 2 , Ta 2 O 5 , WO 2 , WO 3 , ReO 2 , OsO 2 , IrO 2 , PtO, PtO 2 , HgO, Hg 2 O, Tl 2 O 3 , PbO, Pb 2 O 3 , Pb 3 O 4 , PbO 2 , PoO 2 , Bi 2 O 3 , NbO, RuO 2 , Rh 2 O 3 , RhO 2 , PdO, Ag 2 O, AgO, CdO, and In 2 O 3 .
3. The method according to claim 2 , wherein the metal oxide is HfO 2 .
4. The method according to claim 1 , wherein the size of the nanoparticle or nanoparticle aggregate is between around 10 and 200 nm.
5. The method according to claim 1 , wherein said ionizing radiations are selected from the group consisting of X-Rays, γ-Rays, electron beams and radioisotope emissions.
6. The method according to claim 1 , wherein the ionizing radiations are of about 2 KeV to about 25 000 KeV.
7. The method according to claim 6 , wherein the ionizing radiations are of about 2 KeV to 6000 KeV.
8. The method according to claim 6 , wherein the ionizing radiations are of about 2 KeV to 1500 KeV.
9. The method according to claim 1 , wherein the nanoparticle or nanoparticle aggregate consists of a metal oxide having an effective atomic number (Z eff ) of at least 50.
10. The method according to claim 1 , wherein the nanoparticle or nanoparticle aggregate is essentially spherical in shape.
11. The method according to claim 1 , wherein target cells are selected in the group consisting of benign cells, pre-malignant cells and malignant cells.
12. The method according to claim 11 , wherein said malignant cells are cells from a tumor selected from the group consisting of a hematological tumor and a solid tumor.
13. The method according to claim 1 , wherein the pharmaceutical composition further comprises an additional therapeutic anti-cancer compound, said therapeutic compound being distinct from said nanoparticle or nanoparticle aggregate.
14. The method according to claim 1 , wherein said animal is a human.
15. A pharmaceutical composition for altering, destroying, or eliminating target cells in a mammal when said cells are exposed to ionizing radiations, said pharmaceutical composition comprising a nanoparticle or nanoparticle aggregate and a pharmaceutically acceptable excipient, wherein the nanoparticle or nanoparticle aggregate consists of a metal oxide coated with a biocompatible coating, the density of the nanoparticle or the density of the nanoparticle aggregate is of at least 7 g/cm 3 , and the nanoparticle or nanoparticle aggregate is covered with a biocompatible coating providing the nanoparticle or nanoparticle aggregate stability between pH 6.5 and 7.5 in a physiological fluid.
16. A pharmaceutical composition comprising a nanoparticle or nanoparticle aggregate and a pharmaceutically acceptable excipient, wherein the nanoparticle or nanoparticle aggregate consists of a metal oxide coated with a biocompatible coating, the density of the nanoparticle or the density of the nanoparticle aggregate being at least 7 g/cm 3 and less than 15 g/cm 3 , the nanoparticle or nanoparticle aggregate being covered with a biocompatible coating providing stability between pH 6.5 and 7.5 in a physiological fluid.
17. The method according to claim 1 , wherein said biocompatible coating is selected from the group consisting of an inorganic agent, a metallic agent, an organic agent, and mixtures or combinations thereof.
18. The method according to claim 17 , wherein said is selected from the group consisting of an oxide, an hydroxide, an oxyhydroxide and mixtures or combinations thereof.
19. The method according to claim 18 , wherein the oxide, hydroxide or oxyhydroxide contains silicium, aluminum, zirconium, calcium, magnesium and/or tin.
20. The method according to claim 17 , wherein said biocompatible coating is gold, silver or platinum.
21. The method according to claim 17 , wherein said biocompatible coating is a polyethylene glycol (PEG), polyethylenoxide, polyvinylalcohol, polyacrylate, polyacrylamide (poly(N-isopropylacrylamide)), polycarbamide, dextran, xylan, cellulose, collagen, or a zwitterionic compound.
22. The method according to claim 17 , wherein said biocompatible coating is sodium trimetaphosphate (STMP) or sodium hexametaphosphate (HMP).